pyronaridine / Armaceutica - LARVOL DELTA

US Patent Granted Titled: Bifunctional Compositions for the Treatment of Cancer - "US patent granted titled: Bifunctional Compositions for the Treatment of Cancer. This drug, which is often used to treat malaria, is being repurposed by Armaceutica, Inc. to treat various types of cancer....Pyronaridine was shown to preferentially kill certain types of leukemia, lymphoma, melanoma, multiple myeloma, lung, ovarian, and breast cancer cells while limiting off-target toxicities in normal, healthy cells. That is, pyronaridine had reduced effects on non-cancerous cells with a favorable selective cytotoxicity index (SCI), as compared with cancerous cells....Patent offices in Australia, Canada, EU, Israel, Japan, Malaysia, Mexico, Philippines, Russia, Thailand and the UK have granted patents corresponding to U S Patent No.: 12,201,626."

Patent • Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Melanoma • Oncology • Ovarian Cancer

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2a | N=200 | Recruiting | Sponsor: Armaceutica, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2023 ➔ Mar 2024 | Trial primary completion date: Nov 2023 ➔ Feb 2024

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2a | N=200 | Not yet recruiting | Sponsor: Armaceutica, Inc. | Trial completion date: Sep 2023 ➔ Dec 2023 | Initiation date: May 2022 ➔ Aug 2022 | Trial primary completion date: Aug 2023 ➔ Nov 2023

Trial completion date • Trial initiation date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2a | N=200 | Not yet recruiting | Sponsor: Armaceutica, Inc. | Trial primary completion date: Dec 2022 ➔ Aug 2023

Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - P2a | N=200 | Not yet recruiting | Sponsor: Armaceutica, Inc.

New P2a trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology